Stryker
Manufactures orthopedic and surgical medical devices
Assistant Corporate Controller
More locations: Kalamazoo, MI, USA
Hybrid work arrangement with 30% travel.
About the job
- A bachelor's degree in Accounting, Finance, Economics, or Business is required.
- Certified Public Accountant certification is required.
- Twelve or more years of progressive accounting or finance experience, including leadership roles in a large public company, is required.
- Strong knowledge of U.S. generally accepted accounting principles, Securities and Exchange Commission reporting, and Sarbanes-Oxley compliance is required.
- Experience with a Big Four accounting firm is required.
- Expertise in business combinations and complex technical accounting matters is required.
- Ability to lead teams, motivate others, and influence stakeholders across a matrixed global organization is required.
- Business acumen, critical thinking, and problem-solving abilities are required.
- Verbal, written, and interpersonal communication skills, including experience interacting with senior executives and audit committees, are required.
- Ability to organize work, maintain attention to detail, and manage competing priorities in a fast-paced environment is required.
- Demonstrated success driving process improvement, operational excellence, and scalable financial processes is required.
- Ability to work in a hybrid arrangement and travel approximately 30% is required.
- Lead the corporate accounting organization in preparing accurate, timely, and complete consolidated financial statements in accordance with U.S. generally accepted accounting principles and Securities and Exchange Commission requirements.
- Oversee month-end, quarter-end, and year-end close processes, including review of critical estimates, reserves, and key account reconciliations.
- Ensure compliance with Sarbanes-Oxley requirements through the design, execution, and documentation of internal controls and remediation of control gaps.
- Provide technical accounting leadership for revenue recognition, business combinations, impairments, leases, restructuring, and emerging topics.
- Lead the preparation, review, and filing of Securities and Exchange Commission reports, including Forms 10-K, 10-Q, and 8-K, and other disclosures.
- Serve as the primary liaison with external auditors for quarterly reviews and the annual audit, ensuring timely resolution of audit issues.
- Oversee global accounting operations and drive accuracy, efficiency, and process standardization.
- Lead global policy development, process standardization, and continuous improvement across the controllership function.
- Ensure corporate accounting policies are defined, communicated, and consistently applied across divisions and regions.
- Support accounting and financial modeling for business development activities, including due diligence and integration.
- Lead, develop, and mentor the accounting team, set expectations, provide coaching, and build succession plans.
- Collaborate with senior finance and business leaders as an advisor on accounting, controls, and reporting matters.
- Drive finance transformation initiatives involving systems, process standardization, automation, and data quality.
- Support mergers and acquisitions, system implementations, global finance optimization, and strategic growth programs.
- Provide thought leadership on profitability, cost efficiency, and scalable financial processes supporting global expansion.
- Provide executive oversight and strategic direction for global technical finance training programs, including Core trainings and FTD Academy.
- Integrate technical training programs with controllership priorities to strengthen global financial governance and accounting consistency.
- Partner with subject-matter experts to develop training content for advanced technical accounting, U.S. generally accepted accounting principles updates, and finance systems.
- Align global training with revenue recognition, business combinations, impairments, and other complex technical accounting matters.
- Oversee training metrics, key performance indicators, and reporting to assess training effectiveness and organizational capability impact.
- An advanced degree, such as a Master of Business Administration or master's degree in Accounting, is preferred.
About the company
Stryker designs, manufactures, and sells medical devices across multiple areas, including surgical equipment, neurotechnology, and orthopedic implants, to hospitals and clinics worldwide. Its products are developed through engineering and clinical input, then manufactured and distributed to healthcare providers who use them during procedures to improve patient care and surgical efficiency. Stryker differentiates itself from competitors with a broad, integrated portfolio, a global sales and service network, and a strong emphasis on quality and ongoing product development to support safer, more efficient procedures. The company’s goal is to advance patient outcomes by delivering reliable, effective medical devices that expand access to care globally.
Company Size
10,001+
Company Stage
IPO
Headquarters
Kalamazoo, Michigan
Founded
1941
Get referred to Stryker
See people who can refer or advise you
Simplify's Take
What believers are saying
- Second-quarter 2026 sales reached $6.59 billion, with 9.0% organic growth and expanding margins.
- Duke Health completed the first SportSuite Vision surgery on September 1, 2026, validating adoption.
- Stryker won a $100 million Defense Logistics Agency contract modification in August 2026.
What critics are saying
- March 11, 2026 cyberattack disrupted Microsoft systems, manufacturing, and distribution, exposing operational fragility.
- Stryker still carries cyberattack litigation risk after March 2026 employee claims and possible regulator follow-on actions.
- Peripheral vascular backlogs and production recovery threaten Q3 2026 delivery, margins, and customer trust.
What makes Stryker unique
- Mako robotics crossed 2.5 million procedures worldwide across 47 countries by July 2026.
- SportSuite Vision became FDA De Novo authorized on July 17, 2026, for Apple Vision Pro.
- Stryker signed ZuriMED on August 31, 2026, deepening shoulder and rotator cuff specialization.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Medical & prescription plans
Supplemental health benefits
Flexible Spending accounts
Employee Assistance Program
Short-term & long-term disability
Tuition reimbursement
401(k) plan
Employee Stock Purchase Plan
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Stryker has completed the first surgical procedure using its FDA-authorized SportSuite Vision application on Apple Vision Pro at Duke Health. The hip arthroscopy was performed by orthopaedic surgeon Dr Chad Mather III at the academic medical centre. SportSuite Vision received FDA De Novo authorization on 17 July, making it the first application approved for intraoperative use with Apple Vision Pro. The technology allows surgeons to view arthroscopic video, HipCheck, HipMap and CT imaging within their field of vision during procedures. The spatial computing application aims to reduce reliance on traditional monitors positioned throughout operating rooms. By bringing multiple data sources into the surgeon's field of view, it supports a more streamlined and ergonomic surgical workflow during complex arthroscopic procedures.
Stryker has signed a definitive agreement to acquire ZuriMED, a privately held developer of the FiberLocker System for rotator cuff repair. The commercialised soft tissue augmentation technology is designed to provide increased biomechanical strength and reduce clinical failure in rotator cuff procedures. According to Stryker, the acquisition will strengthen its shoulder portfolio and expand support for shoulder specialists across sports medicine and arthroplasty. Rotator cuff augmentation is described as one of the fastest-growing areas in sports medicine and a significant opportunity in shoulder care. The transaction is subject to customary closing conditions. Stryker and ZuriMED will operate as separate entities until closing is complete.
Stryker started 2026 with strong underlying demand despite a cyber disruption. The medical technology company reported 9% organic sales growth in the second quarter, with MedSurg & Neurotechnology rising 9.2% and Orthopaedics up 8.6%. International sales grew 8.9%, supported by markets including Australia, Germany, Canada, India and Brazil. Mako Robotics continues to drive growth, with more than 2.5 million procedures performed globally and systems installed across 47 countries. US knee sales increased 6.2% on continued Mako adoption. The company has a market capitalisation of $125.7 billion. Its bottom line is expected to improve 10.4% over the next five years. However, shares have fallen 6.7% this year, whilst the industry declined 15.2%.
Stryker's Michigan sales unit secured a $100 million contract modification from the US Defense Logistics Agency, reinforcing its position as a key government healthcare supplier. The award complements Stryker's hospital and surgical product revenue, adding government-backed visibility. The company maintains its steady dividend track record, with a quarterly $0.88 per-share payout affirmed in August 2026. However, investors face ongoing concerns including regulatory friction, supply chain pressure, and pricing strain from government payers. Stryker's narrative projects $32.6 billion revenue and $6.5 billion earnings by 2029, requiring 8.9% yearly revenue growth. Fair value estimates from the Simply Wall St Community range from $331 to $426 per share. The contract highlights stable government contracting but does not fundamentally alter Stryker's near-term catalysts or main investment risks.
Stryker shares fell 6.42% following its second-quarter 2026 earnings release, which showed sales of $6.59 billion and net income of $1.28 billion. The medical technology company is now trading approximately 23% below one valuation estimate and 18% beneath the average analyst target. Analysts currently place Stryker's fair value at $386.80, compared to its recent closing price of $325.70. Price targets vary significantly amongst analysts, ranging from $315 to $465. The year-to-date share price return has fallen 6.46%, though the company maintains a five-year total shareholder return of 30.66%. Potential risks to the company's outlook include prolonged EU regulatory delays and sustained supply chain disruptions that could affect product launches and margins.